Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 44, n° 4
pages 634-637 (avril 2001)
Doi : 10.1067/mjd.2001.112357
Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: A preliminary study
 

Başak Yalçin, MD, Sedef Şahin, MD, Gül Bükülmez, MD, Ayşen Karaduman, MD, Nilgün Atakan, MD, Tülin Akan, MD, Fikret Kölemen, MD
Department of Dermatology, Hacettepe University School of Medicine. Ankara, Turkey 

Abstract

Background: PUVA therapy remains a primary treatment for vitiligo, despite unsatisfactory results. Because of calcipotriol's reported effects on melanocytes and on immunomodulatory and inflammatory mediators we wondered whether adding calcipotriol to PUVA would be more effective than PUVA alone in treating vitiligo. Objective: We sought to determine whether the combination of topical calcipotriol and PUVA therapy increases the responsiveness of patients with vitiligo refractory to PUVA alone. Methods: Twenty-one patients with vitiligo refractory to previous PUVA therapy were studied. Patients received 60 sessions of PUVA 3 times a week and 0.005% topical calcipotriol twice daily. Patients were monitored for repigmentation overall and on the trunk, extremities, and acral regions. Results: Starting at the median of the 17th treatment session, some degree of repigmentation was observed in 71.5% of the patients. After treatment, cosmetically acceptable overall repigmentation was observed in 29% of patients; repigmentation of lesions on the trunk, extremities, and acral region was noted in 36%, 58%, and 0% of patients, respectively. Adverse reactions were mild and tolerable. Conclusion: The combination of PUVA and calcipotriol may be effective therapy and should be further investigated for the treatment of vitiligo. (J Am Acad Dermatol 2001;44:634-7.)

The full text of this article is available in PDF format.

 None of the authors had any financial relationship to any commercial association of the products used in the study that might pose a conflict of interest. The study was funded solely through Hacettepe University.
 J Am Acad Dermatol 2001;44:634-7
 Reprint requests: Sedef Şahin, MD, Hacettepe University, Faculty of Medicine, Department of Dermatology, Sihhiye 06100 Ankara, Turkey.



© 2001  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline